2025
Multiomic profiling of LRRC15 in triple negative breast cancer (TNBC).
Morgenstern Kaplan D, Deshmukh S, Wu S, Xiu J, Lopes G, Valdes F, King T, George S, Hurley J, Salazar A, Sucre S, Trapani D, Advani P, Jayachandran P, Lustberg M, Sledge G, Barreto Coelho P. Multiomic profiling of LRRC15 in triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2025, 43: 1098-1098. DOI: 10.1200/jco.2025.43.16_suppl.1098.Peer-Reviewed Original ResearchTriple negative breast cancerCancer-associated fibroblastsImmune cell fractionsH tumorsOverall survivalTumor microenvironmentT cellsHigher expression of immune checkpoint genesAbundance of cancer-associated fibroblastsTNBC heterogeneityExpression of immune checkpoint genesIncreased CAFsT cell inflamed scoreAssociated with better OSCD8+ T cellsInfiltration of B cellsReal-world overall survivalAnalysis of immune cellsFrequency of PIK3CAPositive predictive biomarkerPD-L1 positivityAssociated with poor prognosisImmune checkpoint genesTreatment-related survivalAdverse prognostic biomarkerPD-L1 expression as a negative predictive biomarker in advanced esophageal squamous-cell cancer treated with chemotherapy alone
Sachdeva M, Zhao J, Zhu K, Yap D, Wong N, Kumarakulasinghe N, Tey J, Sundar R. PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous-cell cancer treated with chemotherapy alone. ESMO Gastrointestinal Oncology 2025, 7: 100109. DOI: 10.1016/j.esmogo.2024.100109.Peer-Reviewed Original ResearchAdvanced esophageal squamous-cell carcinomaPD-L1 expressionProgression-free survivalFirst-line chemotherapyPD-L1Overall survivalPredictive biomarkersKaplan-MeierKaplan-Meier (KM)Estimate time-to-event outcomesPatients treated with first-line chemotherapyNegative predictor of OSPhase III randomized trialRisk of tumor progressionProgression-free survival analysisPatients treated with chemotherapyCancer treated with chemotherapyNegative predictive biomarkerNon-significant increased riskPD-L1 subgroupsPositive predictive biomarkerEsophageal squamous-cell carcinomaPredictors of OSIndividual Patient Data Meta-AnalysisResponse to immunotherapy
2023
PD-L1 expression as a unique negative predictive biomarker in advanced squamous NSCLC when treated with first-line chemotherapy.
Wong Zhun Hong N, Zhao J, Zhu K, Yap D, Kumarakulasinghe N, Huang Y, Sundar R. PD-L1 expression as a unique negative predictive biomarker in advanced squamous NSCLC when treated with first-line chemotherapy. Journal Of Clinical Oncology 2023, 41: e21140-e21140. DOI: 10.1200/jco.2023.41.16_suppl.e21140.Peer-Reviewed Original ResearchNon-small cell lung cancerPD-L1 expressionFirst-line chemotherapyNon-squamous non-small cell lung cancerSquamous non-small cell lung cancerTreated with first-line chemotherapyPhase III randomized trialNegative predictive biomarkerNon-squamous histologyPD-L1 subgroupsPD-L1Tumor progressionSquamous histologyPredictive biomarkersKaplan-MeierAdvanced squamous non-small cell lung cancerAdvanced non-small cell lung cancerPatients treated with first-line chemotherapyRandomized trialsInvestigated PD-L1 expressionRisk of tumor progressionHigh PD-L1Kaplan-Meier (KM) curvesPositive predictive biomarkerImmune checkpoint inhibition
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply